期刊文献+

利伐沙班的合成工艺改进 被引量:1

Improved Synthetic Process of Rivaroxaban
原文传递
导出
摘要 (S)-4-氯-3-羟基丁腈与邻苯二甲酰亚胺钾盐反应后,经腈基水解得(S)-4-(1,3-二氧代异吲哚-2-基)-3-羟基丁酰胺,在二(三氟乙酸)碘苯作用下经Hofmann重排得(S)-2-[[2-氧代-1,3-噁唑烷-5-基]甲基]-1H-异吲哚-1,3(2H)-二酮,与4-(4-溴苯基)吗啉-3-酮发生Ullmann偶联得2-[[(S)-2-氧代-3-[4-(3-氧代-4-吗啉基)苯基]-1,3-噁唑烷-5-基]甲基]-1H-异吲哚-1,3(2H)-二酮,再经肼解、酰胺化得利伐沙班,总收率72.7%[以(S)-4-氯-3-羟基丁腈计]。 (S)-4-Chloro-3-hydroxybutanenitrile reacted with phthalimide potassium followed by hydrolysis of nitrile-group to give (S)-4-(1,3-dioxoisoindolin-2-yl)-3-hydroxybutanamide, which was subjected to Hofmann rearrangement in the presence of [bis (trifluoroacetoxy)iodo]benzene to afford (S)-2-[ (2-oxo-l,3-oxazolidin-5- yl) methyl]- 1H-isoindolin-1,3 (2H)-dione, the latter reacted with 4-(4-bromophenyl)morpholin-3-one via Ullmann reaction to give 2- [ [ (S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] - 1,3-oxazolidin-5-1y] methyl] -1H-isoindolin- 1,3 (2H) -dione, then it was subjected to hydrazinolysis and amidation to prepare rivaroxaban with an overall yield of 72.7 % [based on (S) -4-chloro-3-hvdroxvbutanenitrile].
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2017年第2期159-162,共4页 Chinese Journal of Pharmaceuticals
关键词 利伐沙班 抗凝药 合成工艺 rivaroxaban anticoagulant drug synthetic process
  • 相关文献

参考文献5

二级参考文献56

  • 1路新华,郑智慧,马瑛,石英,董悦生,任晓,穆栋,张华,贺建功.微生物来源的Xa因子抑制剂F02-2172的研究[J].中国抗生素杂志,2007,32(5):277-279. 被引量:9
  • 2European Medicines Agency. European Public Assessment Report (EPAR) Xarelto, EMEA/H/C/944 [ EB/OL ]. [ 2008 - 10 - 11 ]. http://www. emea. europa. eu/humandoes/PDFs/EPAR/xareho/H-94-en1. pdf
  • 3European Medicines Agency. European Public Assessment Report (EPAR) Xarelto, EMEA/H/C/944 [ EB/OL ]. [ 2008 - 10 - 11 ]., http://www. emea. europa, eu/humandocs/Humans/EPAR/xarelto/xarelto. htm.
  • 4ROEHRIG S, STRAUB A, POHLMANN J. Discovery of the novel antithrombotic agent 5 -chloro-N- ( │( 5 S ) -2-ox0-3 - [ 4- ( 3 -oxomorpholin-4-yl) phenyl ] -1,3-oxazolidin-5-yl │ methyl ) thiophene- 2-carboxamide (BAY 59-7939) : an oral, direct factor Xa inhibitor[ J]. J Med Chem,2005,48 ( 19 ) :5900 - 5908.
  • 5DAURE EW, FUJIKAWA K, KISIEL W. The coagulation cascude: Initiation, maintenance and regulation [ J ]. Biochemistry, 1991,30(43) :10363 - 10370.
  • 6WEINZ C, BUETEHORN U,DAEHLER HP, et al. Pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in rats and dogs [ J ]. Xenobiotica, 2005,35 ( 9 ) : 891 -910
  • 7KUBITZA D, BECKA M, ZUEHLSDOR M, et al. Effect of Food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (Rivaroxaban) , an oral, direct factor Xa inhibitor, in healthy subjects [ J ]. J Clin Pharm, 2006,46 ( 6 ) : 549 - 558.
  • 8LASSEN MR, TUPRPIE AG, ROSENCHER N, et al. Rivaroxaban an oral, direct factor Xa inhibitor for thromboprophylaxis after totalknee arthroplasty: The RECORD3 Trial. (Abstract No.308). American Society of Hematology. 49th Annual Meeting. Atlanta. December 2007 [ EB/OL]. [ 2007 - 11 - 16 ]. http:// www. abstracts2view. com/hem07/view. php? nu = HEM07L1-2447.
  • 9Pivotal phase III data showed rivaroxaban was statistically superior to enoxaparin in preventing venous thromboembolism (VTE) in patients following hip replacement surgery. NewYork: BusinessWire[ EB/OL]. [ 2007 - 12 -08 ]. http ://proquest. umi. com/ pqdweb? did = 1395271941&sid = 1&Fmt = 7&clientld = 26489&RQT = 309&VName = PQD.
  • 10HARRY BR, ANTHONIE LWA, MARTIN PH. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein_DVT Dose-Ranging Study [ J ]. Blood, 2008, 6 ( 112 ) :2242 - 2247.

共引文献23

同被引文献9

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部